🔗 Visit the ClinicalTrials.gov page for NCT01554852
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. | J Clin Oncol | 2015 | 1.49 |
| 2 | APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. | Nat Commun | 2015 | 1.14 |
| 3 | Bortezomib in multiple myeloma: systematic review and clinical considerations. | Curr Oncol | 2014 | 0.93 |
| 4 | Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo. | Acta Pharmacol Sin | 2013 | 0.91 |
| 5 | The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. | Ther Adv Hematol | 2014 | 0.88 |
| 6 | The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. | Clin Cancer Res | 2016 | 0.77 |